Gustavo Viani: The Case for Two-Fraction SBRT in Prostate Cancer Treatment
Gustavo Viani, Professor of Radiation Oncology at Ribeirão Preto Medical School, shared an article Cristian Udovicich and colleagues authored on X:
“Fewer Sessions, Same Results? The Case for Two-Fraction SBRT in Prostate Cancer Treatment
Objective
• Compare 2F-SBRT vs. 5F-SBRT for IR-PC
Methods
• Meta-analysis of 199 participants from four prospective trials
• 2F-SBRT: 56 participants (26 Gy in 2 fr)
• 5F-SBRT: 143 participants (40 Gy in 5 fr)
• Median follow-up: 9.4 years.
• Primary endpoint: Biochemical failure (BCF)
Results
• No difference in 5-year BCF:
• 2F-SBRT: 3.6% vs. 5F-SBRT: 6.0% (p = 0.73).
• Distant metastases and survival: same between groups
QoL
• No significant differences in urinary, bowel, or sexual function
• Hormonal QoL decline: high in 2F-SBRT (52% vs. 19%).
Clinical Implications
• 2F-SBRT is as effective as 5F-SBRT with same toxicity
• Supports further investigation of 2F-SBRT as a potential new standard of care”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023